---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-001049"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-02-16T23:59:59+00:00"
generated_at: "2026-06-06T00:11:08.568485+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Majority shareholder approves warrant adjustments for Sunshine Biopharma

## Summary
- Dr. Steve Slilaty (CEO, 58.3% voting power) approved written consent on Feb 13, 2024.
- Consent covers alternative cashless exercise for Series A Warrants and adjustments upon share combination.
- Also includes voluntary exercise price adjustments, Floor Price clause inapplicability for Series B, and dilutive issuance adjustments.
- Effective 20 days after mailing information statement to shareholders.

## SEC filing metadata
- accession: 0001683168-24-001049
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-02-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-001049
- JSON: https://secwatch.observer/filing/0001683168-24-001049.json
- Plain text: https://secwatch.observer/filing/0001683168-24-001049.txt

## Key facts
- Shareholder Votes
  Sunshine Biopharma Inc. shareholders approved Voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding Warrants pursuant to Section 3.8 of the Series A Warrants and 3.9 of the Series B Warrants at the 2024-02-13 meeting.
  - Outcome: passed
  - Meeting: 2024-02-13
  source text: On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm
- Shareholder Votes
  Sunshine Biopharma Inc. shareholders approved Give full effect to the adjustment in the exercise price and number of Warrant Shares as defined in the Series B Warrants following a Dilutive Issuance as defined in the Series B Warrants pursuant to Section 3.2 of the Series B Warrants at the 2024-02-13 meeting.
  - Outcome: passed
  - Meeting: 2024-02-13
  source text: On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm
- Shareholder Votes
  Sunshine Biopharma Inc. shareholders approved Give full effect to alternative cashless exercises pursuant to Section 2.3 of the Series A Warrants at the 2024-02-13 meeting.
  - Outcome: passed
  - Meeting: 2024-02-13
  source text: On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm
- Shareholder Votes
  Sunshine Biopharma Inc. shareholders approved Any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants in the event of a Share Combination Event as defined in the Series A Warrants and Series B Warrants in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warra at the 2024-02-13 meeting.
  - Outcome: passed
  - Meeting: 2024-02-13
  source text: On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm
- Shareholder Votes
  Sunshine Biopharma Inc. shareholders approved Render inapplicable clause (i) of the definition of the Floor Price as defined in the Series B Warrant in Section 3.2 of the Series B Warrants at the 2024-02-13 meeting.
  - Outcome: passed
  - Meeting: 2024-02-13
  source text: On February 13, 2024, Dr. Steve Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma, Inc. (the “Company”), approved by written consent: · to give full effect to alternative cashless exercises pursuant to Section ‎2.3 of the Series A Warrants (the “Series A Warrants”) issued pursuant to the underwriting agreement (the “Underwriting Agreement”), dated February 13, 2024, between the Company and Aegis Capital Corp., as underwriter; · to any adjustment to the exercise price or number of shares of common stock underlying the Series A Warrants or the Series B Warrants (issued pursuant to the Underwriting Agreement) (the “Series B Warrants,” and collectively with the Series A Warrants, the “Warrants”) in the event of a Share Combination Event (as defined in the Series A Warrants and Series B Warrants) in Section 3.7 of the Series A Warrants and 3.8 of the Series B Warrants; · to the voluntary adjustment, from time to time, of the exercise price
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824001049/0001683168-24-001049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.